PlexBio, a leader in precision medicine, has announced that its innovative IntelliPrep TRIO 240 Fully Automated Sample Preparation System received FDA certification this month. In addition, the company has signed a distribution agreement with Chris & Paul, a Korean distributor, to introduce the system to the Korean market. Moving forward, Diagenex will handle its promotion and sales, offering groundbreaking advancements for molecular diagnostics in Korea.
PlexBio stated that receiving FDA approval and successfully entering the Korean market represent significant milestones for the company. This collaboration with Korea underscores the strong alignment between PlexBio’s technological innovations and international market demands. Through its partnership with Diagenex, PlexBio plans to deepen its presence in Korea, providing local medical institutions with more efficient and accurate diagnostic technologies, thus accelerating the development of precision medicine in the region.
PlexBio specializes in in-vitro diagnostic reagents and laboratory equipment. With the rapid rise of global precision medicine and the growing demand for cancer genetic molecular testing, ensuring accurate, efficient sample preparation is critical. To address this, PlexBio developed the world's first IntelliPrep TRIO 240 Fully Automated Sample Preparation System, designed to process a variety of sample types—including tissue, blood, saliva, and pleural effusions. The system automates nucleic acid extraction, quantification, and PCR preparation based on the quantified results, significantly improving testing efficiency and accuracy.
The IntelliPrep TRIO 240 features a proprietary magnetic bead liquid handling technology, offering an all-in-one solution for nucleic acid extraction, DNA quantification, and PCR preparation. The system is particularly well-suited for formalin-fixed paraffin-embedded (FFPE) cancer tissue samples, providing a complete and efficient nucleic acid extraction process without requiring lengthy pre-treatment procedures. This innovation streamlines pathology workflows, making diagnostic processes faster and more precise.
PlexBio's continued expansion into global markets and its innovative product lineup position the company as a key player in driving the future of precision medicine. The introduction of IntelliPrep TRIO 240 into Korea is expected to set new standards for molecular diagnostics and elevate the quality of care available to patients.
Resource: 博錸生技全自動檢體製備系統獲FDA認可、授權韓國經銷
